
You Should Know: C3 Jian
by Thomas Giacobbi, DDS, FAGD, Editorial Director, Dentaltown Magazine
Randy Eckert is a laboratory director, and co-founder of C3 Jian, founded in 2006. The name, which references the founders (C3) and
Jian, which means archer or targeted in Chinese, has developed a complex and technological recipe for a mouthrinse that just might
be the secret to eliminating Strep mutans, and eventually, caries.
What is the general mission statement of C3?
Eckert: To address diseases of demineralization in the
oral cavity, specifically dental caries.
And how did fulfilling the mission start?
Eckert: We started with the technology side first. Kind
of stepping back and giving you a bird’s eye view of the
development, we started out from the research side. We
took a look from our deep understanding of oral microbiology
and took a look at interplay between the species
within in the oral cavity. There are hundreds of species in
the oral cavity and there is a great deal of competition and
cooperation that occurs. One of the interesting findings is
that the Strep mutans become dominant when you have a
lot of dietary sugars because they make these antimicrobial
compounds and they kill other bacteria, but as a whole they
are a minority in their own niche. They are one of only a
handful of acid-producing bacteria and although they produce
the majority of acid involved in caries, they are alone
in that role, so we see right away that there are all these
potentially beneficial bacterial occupying the same niches as
mutans. There is an opportunity for targeted therapy to be
more than just selective removal of a pathogen. There is a
whole other side to it – if we get rid of S. mutans selectively,
the other bacteria can then fill in the niche and provide you
with longer term protection. You are basically changing the
ecology in the mouth. How do you get rid of S. mutans
selectively and let the normal flora give you protective
colonization? One of the things we have worked on are
peptide compounds. Peptides are a convenient chemical
canvas, without getting too technical. Basically these peptides
can be easily tailored to do what we want, which in
this case is to make selectively targeted antibiotic.
That gave us the molecular framework to get the job
done. Then the last step was figuring out how to deploy it
to the oral cavity. Mouthrinse is the easiest thing because it
is topical. Our antibiotic is very rapid. It only needs 30 or
40 seconds in there, gets all the S. mutans out and then you
spit it all out.
How often do you need to do the rinsing?
Eckert: It is intended to be formulated by the dentist
or hygienist chairside. It will come in a kit with a mouthrinse
vehicle and then the powdered peptide antibiotic
component. We are intending for it to be used infrequently
to aid in maintaining the natural S. mutans-free
dental plaque. Ideally it will fit into the typical every sixmonths
prophy visit.
It looks like your recent research was done in
conjunction with, or with support from Colgate, is
that correct?
Eckert: We were in a joint research agreement at
the time, but the commercial rights to the product
have always rested with C3, and we still retain worldwide
exclusive license. We have all the key patents for
this technology and after seeing how well this was
working, our board of directors has made a strategic
decision to go forward without a partner. That is where
we are right now.
So how does all this affect the elimination of new
decay and demineralization? And how close does
it get us to “cavity-free?”
Eckert: We are eliminating the root cause so then you
prevent further damage. I think the important thing to realize
is we are not a replacement for fluoride. This product is
one that can work in conjunction with an agent like fluoride
that repairs the damage because if you are going to take
this you might have some existing damage already in your
tooth structure and this isn’t going to fix damage. It will
eliminate the cause, but something like fluoride is still foreign
because it rebuilds that enamel.
How many people are working on this project?
Eckert: We are a small company at the moment but we
are rapidly expanding. We have only about 20 employees
now but we are going to be tripling in size very shortly. We
are expanding.
|